Atlas Trials

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT04221555 · COMPLETED

Trial details

NCT number
NCT04221555
Sponsor
Asan Medical Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Start date
2020-05-13
Primary completion
2025-04-08
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.